Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Medtronic, Inc.    

SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Medtronic, Inc. : Medtronic Endurant® AAA Stent Graft Shows Durable Performance at Two Years in U.S. Study

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/16/2012 | 01:05pm CET

Market-Leading Medical Device for Minimally Invasive Treatment of Abdominal Aortic Aneurysms Continues to Demonstrate Strong Safety and Efficacy

Bolstering confidence in endovascular repair of abdominal aortic aneurysms (AAA), Medtronic Inc. (NYSE:MDT) announced yesterday the two-year results from its U.S. clinical study of the Endurant AAA Stent Graft System, the global market leader in its product category.

Presented at this year's Charing Cross International Symposium (CX34) in London, the prospective Endurant U.S. investigational device exemption (IDE) study's complete results at two years continue to demonstrate durable clinical performance with strong safety and efficacy in long-term follow-up. These results add to a growing body of evidence on the Endurant AAA Stent Graft, which continues to deliver consistent clinical results in both controlled trials and real-world registries.

"The Endurant Stent Graft is performing just as well at two years as it did at one year, with no aneurysm-related mortalities, migrations or conversions," said the study's principal investigator, Dr. Michel Makaroun, professor and chief of vascular surgery at the University of Pittsburgh School of Medicine. "Freedom from aneurysm-related mortality and secondary interventions demonstrate favorable trends versus earlier generation devices. This finding will continue to play a critical role in improving the minimally-invasive treatment of patients with abdominal aortic aneurysms."

The Endurant U.S. IDE study enrolled 150 AAA patients at 26 U.S. medical centers. Significant to clinical practice, the study included patients with "landing zones," or healthy aortic neck lengths, as short as 10 mm, whereas most other trials of aortic stent grafts have required neck lengths of at least 15 mm. The study also monitored changes in aneurysm size and stent graft migration, a concern with current endovascular treatment, as well as the occurrence and type of endoleaks.

The study found that nearly all (97.6 percent) of the aneurysm sacs that were treated with the Endurant AAA Stent Graft decreased or remained stable in size at two years post-procedure, with only 0.8 percent Type I endoleaks and no Type III endoleaks.

In collaboration with leading clinicians, researchers and scientists, Medtronic offers the broadest range of innovative medical technology for the interventional and surgical treatment of cardiovascular disease and cardiac arrhythmias. The company strives to offer products and services that deliver clinical and economic value to healthcare consumers and providers worldwide.

ABOUT MEDTRONIC

Medtronic, Inc. (www.medtronic.com), headquartered in Minneapolis, is the global leader in medical technology -- alleviating pain, restoring health and extending life for millions of people around the world.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

Medtronic, Inc.
Public Relations
Joe McGrath, 707-591-7367
Investor Relations
Jeff Warren, 763-505-2696


© Business Wire 2012
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MEDTRONIC, INC.
05:01p MEDTRONIC : EVP & RTG President Geoffrey S. Martha to Speak at Cowen Healthcare ..
03:57p MEDTRONIC : Receives CE Mark for Its Next Generation Cardiac Resynchronization T..
09:16a MEDTRONIC : The Cetera Advisors Llc Sells 23,049 Shares of Medtronic Plc (Mdt)
02/24 MEDTRONIC : New Solitaire Stent Retriever Study Validates Outcomes and Real-Worl..
02/24 MEDTRONIC : New Solitaire(TM) Stent Retriever Study Validates Outcomes and Real-..
02/24 MEDTRONIC : Receives CE Mark for Its Next Generation Cardiac Resynchronization T..
02/24 MEDTRONIC : Combine Solicitation - 65-- 583-17-2-096-1086 KYPHOPLASTY TRAYS
02/24 MEDTRONIC : MILITARY $5,204 Federal Contract Awarded to Medtronic
02/24 MAZOR ROBOTICS : Reports Record Fourth Quarter and Full Year 2016 Results
02/23 MEDTRONIC : New Solitaire(TM) Stent Retriever Study Validates Outcomes and Real-..
More news
Sector news : Medical Equipment, Supplies & Distribution - NEC
02/16 STRAUMANN : on hunt for 3D printer partner, could take stake - CEO
02/09 Smith & Nephew hurt by tough markets in China and Gulf states
02/02DJBECTON DICKINSON AND : Earnings Jump, and It Raises 2017 Outlook
02/01DJBAXTER INTERNATIONAL : Profit Climbs 19%
01/31DJZIMMER BIOMET : Hip, Knee Businesses Drive Results
More sector news : Medical Equipment, Supplies & Distribution - NEC
News from SeekingAlpha
2015 DIVIDEND INCOME UPDATE : January 2015
2015 FDA clears Medtronic transcatheter heart valve
2015 Dividend Aristocrats And A Fundamental Principle Of Dividend Growth Investing
2015 Boston Scientific Awaits Court Decision
2015 The DGI 'Factual 48' Versus 'The Favored 44'
Advertisement
Financials ($)
Sales 2017 29 658 M
EBIT 2017 8 308 M
Net income 2017 4 571 M
Debt 2017 23 282 M
Yield 2017 2,10%
P/E ratio 2017 25,23
P/E ratio 2018 21,94
EV / Sales 2017 4,54x
EV / Sales 2018 4,31x
Capitalization 111 258 M
More Financials
Chart MEDTRONIC, INC.
Duration : Period :
Medtronic, Inc. Technical Analysis Chart | US5850551061 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 88,0 $
Spread / Average Target 8,6%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Omar S. Ishrak Chairman & Chief Executive Officer
Karen L. Parkhill Chief Financial Officer & Executive Vice President
Richard E. Kuntz Chief Scientific, Clinical & Regulatory Officer
Richard H. Anderson Lead Independent Director
Craig Arnold Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
MEDTRONIC, INC.0.78%111 258
MEDTRONIC PLC13.76%111 258
BAXTER INTERNATIONAL I..13.87%27 463
ZIMMER BIOMET HOLDINGS..13.29%23 419
C R BARD INC9.13%17 660
HOYA CORPORATION3.13%17 633
More Results